A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations Who Are Ineligible for Intensive Chemotherapy
The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutation in the NPM1 or KMT2A gene.
Inclusion criteria:
Exclusion criteria:
Participate-In-This-Study1@its.jnj.com844-434-4210
Orlando, Florida 32804, United States
Hackensack, New Jersey 07601, United States
Winston-Salem, North Carolina 27157, United States
Portland, Oregon 97225, United States
Richmond, Virginia 23298, United States
Rio de Janeiro, 22775 001, Brazil
São Paulo, 05652 900, Brazil
Montreal, Quebec H1T 2M4, Canada
Hangzhou, 310003, China
Tijian, 300020, China
Wuhan, 430022, China
Wuhan, 430030, China
Ostrava - Poruba, 708 52, Czechia
Vandœuvre Ies-Nancy, 54500, France
Chaïdári, 124 62, Greece
Budapest, 1097, Hungary
Beer Yaakov, 7033001, Israel
Reggio Calabria, 89124, Italy
Torino, 10126, Italy
Bunkyō City, 113 8677, Japan
Mexico City, 14080, Mexico
Lodz, 93 513, Poland
Wroclaw, 50 367, Poland
Ankara, 06200, Turkey (Türkiye)